C12 boost RT + Erbitux for adenoid cystic carcinomas (ACC)
The ACCEPT trial has followed the COSMIC trial in the treatment of adenoid cystic carcinomas (ACC) of the head and neck. However, in this trial only ACC patients with macroscopic residual disease can be included. Patients receive carbon ion boost of 6 x 3 GyE to the high risk area in conjunction with a 27 x 2 Gy photon IMRT of the extended CTC. In addition, all patients receive the EGFR antibody Cetuximab on a weekly basis. Primary endpoint is toxicity (mucosistis grade IV) to evaluate toxicity and feasibility of Cetuximab and carbon ion irradiation in the treatment of ACCs. Secondary endpoints are local control, metastases free survival and disease free survival. A total of 50 patients are planned for this study and recruitment is under way. More details about the trial has been published previously .